Abstract
Lung cancer is the leading cause of cancer related deaths worldwide. Although targeting the cell cycle of cancer cells has been a promising approach, no such therapy has translated for the treatment of lung cancer. In our previous work, we identified that the combinatorial treatment of two miRNAs, miR-143 and miR-506, inhibited the cell cycle of lung cancer cells in vitro. These miRs downregulated the CDK1 and CDK4/6 genes, which are involved in the G1/S and G2/M transitions, respectively. Nucleic acid delivery has met formidable challenges, such as short in vivo half-life and rapid degradation in the circulation, as well as limited cell penetration or endosomal escape. We developed a novel nanocarrier, composed of tocopherol (vitamin E), polyethylenenimine, and polyethylene glycol (TPP) in 1:1:1 molar ratio for the delivery of miRNAs. Proper characterization with NMR and FTIR confirmed the synthesis of this molecule. We found it can form nanomicelles, and the positively charged of polyethyleneimine allowed for the complexation of miRNAs, as was detected by a gel retardation assay. Fluorescently tagged TPP micelles were uptaken by cancer cells, and the carrier successfully transfected cancer cells with the combinatorial miRNA treatment inducing gene downregulation. In vivo pharmacokinetics study using a subcutaneous mouse model of lung cancer indicated prolonged accumulation of the TPP-miRNA micelles in the tumor area. In vivo administration of the miR-143/506 in TPP micelles, along with cisplatin co-treatment, inhibited tumor growth in a subcutaneous mouse model of lung cancer. Overall, the promising role of miR-143 and 506 for the regulation of LC growth may be achieved by this novel TPP-based nanocarrier, which merits further evaluation. Citation Format: A K M Nawshad Hossian, Chandra Mohan Reddy Muthumula, George Mattheolabakis. Delivery of miR-143 and miR-506 with novel nano carrier to arrest cell cycle in lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4429.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.